Cargando…
Fully synthetic platform to rapidly generate tetravalent bispecific nanobody–based immunoglobulins
Nanobodies bind a target antigen with a kinetic profile similar to a conventional antibody, but exist as a single heavy chain domain that can be readily multimerized to engage antigen via multiple interactions. Presently, most nanobodies are produced by immunizing camelids; however, platforms for an...
Autores principales: | Misson Mindrebo, Laetitia, Liu, Hejun, Ozorowski, Gabriel, Tran, Quoc, Woehl, Jordan, Khalek, Irene, Smith, Jessica M., Barman, Shawn, Zhao, Fangzhu, Keating, Celina, Limbo, Oliver, Verma, Megan, Liu, Jingjia, Stanfield, Robyn L., Zhu, Xueyong, Turner, Hannah L., Sok, Devin, Huang, Po-Ssu, Burton, Dennis R., Ward, Andrew B., Wilson, Ian A., Jardine, Joseph G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268213/ https://www.ncbi.nlm.nih.gov/pubmed/37276407 http://dx.doi.org/10.1073/pnas.2216612120 |
Ejemplares similares
-
Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways
por: Zhao, Fangzhu, et al.
Publicado: (2022) -
Tetravalent Bispecific Tandem Antibodies Improve Brain Exposure and Efficacy in an Amyloid Transgenic Mouse Model
por: Do, Tuan-Minh, et al.
Publicado: (2020) -
Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds
por: Yu, Lin, et al.
Publicado: (2021) -
A NOVEL IMMUNOSTIMULATORY PD-L1/OX40 TETRAVALENT BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY
por: Li, Baocun, et al.
Publicado: (2023) -
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
por: Pang, Xinghua, et al.
Publicado: (2023)